ALFENTA (alfentanil hydrochloride) by Pfizer is clinical pharmacology alfenta (alfentanil hydrochloride) is an opioid analgesic with a rapid onset of action. First approved in 1986.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
ALFENTA (alfentanil hydrochloride) is a rapid-onset opioid analgesic used for intraoperative analgesia and sedation in surgical and procedural settings. It works as a mu-opioid receptor agonist with a three-compartment pharmacokinetic profile and terminal elimination half-life of 90-111 minutes, enabling quick recovery compared to longer-acting opioids like fentanyl. ALFENTA is administered intravenously at doses ranging from 5-245 mcg/kg depending on procedure duration and patient factors.
As a legacy injectable opioid approaching loss of exclusivity with moderate competitive pressure, the brand team is likely in managed-care and hospital contract defense mode with smaller headcount than growth-stage products.
CLINICAL PHARMACOLOGY ALFENTA (alfentanil hydrochloride) is an opioid analgesic with a rapid onset of action. At doses of 8-40 mcg/kg for surgical procedures lasting up to 30 minutes, ALFENTA provides analgesic protection against hemodynamic responses to surgical stress with recovery times…
Worked on ALFENTA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of a Bolus of 10 µg/kg of Alfentanil on the Pupillary Pain Index
Working on ALFENTA offers exposure to hospital/procedural channel sales, institutional contracting, and GPO management—skills highly transferable to other generic or legacy injectable portfolios. However, the LOE-approaching lifecycle and minimal linked job openings indicate limited growth trajectory; career value lies in operational efficiency and relationship management rather than new product launch experience.